Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The group usually releases earnings worse than estimated.
  • With an enterprise value anticipated at 4.29 times the sales for the current fiscal year, the company turns out to be overvalued.
  • With a 2018 P/E ratio at 23.55 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK AND COMPANY8.90%164 862
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
AMGEN7.07%123 415
ABBOTT LABORATORIES8.88%108 943
BAYER-5.82%105 076
GLAXOSMITHKLINE17.20%102 028
SANOFI-4.93%99 211
ELI LILLY AND COMPANY2.79%93 651
ASTRAZENECA5.04%89 738
BRISTOL-MYERS SQUIBB COMPAN..-12.47%88 674
NOVO NORDISK A/S-13.74%86 122
ALLERGAN PLC5.79%59 401
CELGENE CORPORATION-23.88%57 819
More Results
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,19%
P/E ratio 2018 23,55
P/E ratio 2019 15,92
EV / Sales 2018 4,29x
EV / Sales 2019 4,09x
Capitalization 165 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart MERCK AND COMPANY
Duration : Period : Day
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Duration : Period : Week
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders